Drug Trial Radar · NCT06308406
A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer
Last checked: Nov 20, 2026Latest source record: Apr 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
54
Planned (sponsor's estimate)
Start
Mar 15, 2024
Primary completion
Oct 2025
Study completion Oct 2025
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, open-label Phase Ib/II clinical trial to observe and evaluate the safety, tolerability and pharmacokinetics of HRS-1167 in combination with bevacizumab in patients with recurrent ovarian cancer mechanical characterization and preliminary evaluation of the efficacy of HRS-1167 in combination with bevacizumab in patients with recurrent ovarian cancer.
Conditions
- Recurrent Ovarian Cancer
Interventions
Bevacizumab; HRS-1167Drug
Bevacizumab: injection, 100mg(4mL), intravenous infusion HRS-1167: Tablets, 25mg/tablet, oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of subjects with dose-limiting toxicity (DLT)Time frame: From first dose of study treatment until the end of Cycle 1(up to 21 days)
- Determination of Recommended Phase II dose (RP2D)Time frame: From first dose of study treatment until the end of Cycle 1(up to 21 days)
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China · Not yet recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Not yet recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China · Not yet recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Not yet recruiting
Guangxi Medical University Affiliated Tumor Hospital
Nanning, Guangxi, China · Not yet recruiting
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Not yet recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
Wuhan, Hubei, China · Not yet recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Liaoning Cancer Hospital
Shenyang, Liaoning, China · Not yet recruiting
Qilu Hospital of Shandong University
Jinan, Shandong, China · Not yet recruiting
Shandong First Medical University Affiliated Cancer Hospital
Jinan, Shangdong, China · Not yet recruiting
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, China · Not yet recruiting
Sichuan Cancer Hospital
Chengdu, Sichuan, China · Not yet recruiting
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
Yunnan Cancer Hospital
Kunming, Yunnan, China · Not yet recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.